Hims & Hers Health, Inc.’s HIMS investors are reaping some gains from the stock of late. Shares of the San Francisco, ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health HIMS. And retail traders should know ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Hims & Hers is revolutionizing telehealth and wellness for millennials and Gen Z with rapid revenue growth and positive net ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $23.41 which represents a decrease of $-0.21 or -0.89% from the prior close of $23.62. The stock opened at $23.6 and ...

Bearish flow noted in Hims and Hers Health with 30,788 puts trading, or 9x expected. Most active are Dec-24 21 puts and Dec-24 22 puts, with ...